Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 11th April 2018
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Human anti-cancer drugs could help Tasmanian devils
Tasmanian devils are considered endangered as a result of devil facial tumour 1.
RTKs have ‘an important role’ in sustaining transmissible cancers

Key drugs used to treat cancer in humans may also be useful in the fight against transmissible cancers in Tasmanian devils.

This is according to a new study by the University of Cambridge, which found that certain drugs used in humans were able to efficiently stop the growth of devil cancer cells in the lab.

The research, published in the journal Cancer Cell, shows that molecules known as receptor tyrosine kinases (RTKs) have an important role to play in sustaining the growth and survival of transmissible cancers in devils. Drugs targeting RTKs have already been developed for human cancers.

Tasmanian devils are considered endangered as a result of devil facial tumour 1 (DFT1), which is passed between animals through biting and causes disfiguring facial tumours. Usually fatal, DFT1 has spread throughout Tasmania since it was first seen in 1996, causing significant declines in devil populations.

Routine diagnostic screening in 2014 uncovered a second transmissible cancer in the species. With the naked eye, facial tumours caused by devil facial tumour 2 (DFT2) cannot be distinguished from those caused by DFT1, but analysis has shown they differ at a biological level.

Cambridge researchers found striking similarities between the two cancer types; in terms of genetics, tissues of origin, the way in which the cancer cells mutate and possible drug targets.

First author Dr Elizabeth Murchison said: “The story of Tasmanian devils in recent years has been a very concerning one. This study gives us optimism that anti-cancer drugs that are already in use in humans may offer a chance to assist with conservation efforts for this iconic animal.”

Become a member or log in to add this story to your CPD history

Cold-water dip to raise funds for Vetlife

News Story 1
 The veterinary mental health charity Vetlife is inviting the veterinary community to join it for a sponsored cold-water dip.

The event will take place at Walpole Bay, Margate, on 17 May during Mental Health Awareness Week. Participants of all abilities can join in the challenge and are advised to bring a towel, a hot drink, a snack, and warm clothes to get changed into afterwards.

Those taking part are being asked to try to raise £100 each to support the work of the charity.

Details about how to take part can be found here. 

Click here for more...
News Shorts
Bluetongue low vector period ends

In an update to its bluetongue guidance, the Department for Environment, Food and Rural Affairs (Defra) has announced that the seasonal low vector period for the disease has ended.

With winter over, Defra is planning for a possible increase in cases as midges become more active. It has warned that farms along the east coast of England from Norfolk to Kent, and along the south coast from Kent to Devon, are at highest risk from infected midges blown over from northern Europe.

Since the virus was detected in England in November 2023, there have been 126 confirmed cases. The most recent case to be confirmed was on 1 March 2024.

Farmers are asked to continue to frequently monitor their livestock and ensure their animals and land are registered with the Animal and Plant Health Agency.